Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study

作者：Au Heather Jane; Eiermann Wolfgang; Robert Nicholas J; Pienkowski Tadeusz; Crown John; Martin Miguel; Pawlicki Marek; Chan Arlene; Mackey John; Glaspy John; Pinter Tamas; Liu Mei Ching; Fornander Tommy; Sehdev Sandeep; Ferrero Jean Marc; Bee Valerie; Santana Maria J^*; Miller Dave P; Lalla Deepa; Slamon Dennis J

来源：Oncologist, 2013, 18(7): 812-818.

DOI：10.1634/theoncologist.2013-0091

• Breast cancer
• BCIRG 006
• Docetaxel
• Trastuzumab
• Chemotherapy
• Quality of life
• Anthracycline-induced cardiotoxicity
• Adjuvant therapy

Background. This study aims to describe and compare health-related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast cancer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. %26lt;br%26gt;Methods. Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC -%26gt; T) or one of two trastuzumab-containing regimens: adjuvant doxorubicin and cyclophosphamide followed by docetaxel plustrastuzumab administered for 1 year (AC -%26gt; TH) or six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year (TCH). The European Organization for Research and Treatment of Cancer( EORTC) Quality of Life Questionnaire C30 and BR-23 were administered at baseline, the start of cycle 4(mid), and the end of chemotherapy(EOC), as well as at 6, 12, and 24 months after chemotherapy. %26lt;br%26gt;Results. Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC -%26gt; TH and AC -%26gt; T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC -%26gt; TH regimen, but was otherwise similar between arms. All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up. %26lt;br%26gt;Conclusion. HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.

• 出版日期2013-7